Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Single-cell sequencing and organoids: applications in organ development and disease

Li T., Yin J., Hao Y., Gao W., Li Q., Feng Q.

Narrative Review on Neuroinflammation, published in Mol Biomed (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Mol Biomed (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41359105
PMCID
PMC12686334
DOI
10.1186/s43556-025-00364-6
Citations
5

Abstract (original English)

The integration of single-cell sequencing and organoid technologies has been transformative for biomedical research, enabling investigations of organ development, disease mechanisms, and therapeutic innovation at even finer resolutions. Organoids serve as 3D in vitro models that replicate the structural and functional complexity of human tissues, while single-cell sequencing can resolve cellular heterogeneity, transcriptional dynamics, and lineage trajectories at high resolution. This review systematically explores the synergistic potential of these two technologies across multiple domains. First, it describes their application in studying the developmental mechanisms of organs including the brain, lungs, heart, liver, intestines, and kidneys, revealing key signaling pathways and cellular interaction networks. Then, it details their application in studying in vitro models of various diseases, including neurodegenerative disorders, genetic diseases, infectious diseases, metabolic syndrome, and tumors, advancing the in-depth analysis of pathological mechanisms. By leveraging patient-derived organoid biobanks, combining these two technologies can accelerate drug screening and precision, while utilizing transplantable tissue constructs to pioneer regenerative medicine strategies. This review also highlights the strengths of combining these two technologies in dynamically decoding c

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
OrganoidsAnimalsHumansRegenerative MedicineOrganogenesisSingle-Cell AnalysisPrecision Medicine

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research